Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity by Lundberg, K. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/32323
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
A va ila b le  o n lin e  http://arthritis-research.eom/content/7/3/R458
Research article
Citrullinated proteins have increased immunogenicity and 
arthritogenicity and their presence in arthritic joints correlates 
with disease severity
Karin Lundberg1, Suzanne Nijenhuis2, Erik R Vossenaar2, Karin Palmblad1, Walter J van Venrooij2, 
Lars Klareskog1, AJW Zendman2 and Helena Erlandsson Harris1
Open Access
'Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 
2Department of Biochemistry, Radboud University Nijmegen, Nijmegen, The Netherlands
Corresponding author: Karin Lundberg, karin.lundberg@cmm.ki.se
Received: 21 Oct 2004 Revisions requested: 2 Dec 2004 Revisions received: 16 Dec 2004 Accepted: 20 Jan 2005 Published: 21 Feb 2005
Arthritis Research & Therapy 2005, 7:R458-R467 (DOI 10.11 86/ar1697)
© 2005 Lundberg et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
A u toan tibod ies d irec ted  aga inst c itru lline -con ta in ing  pro te ins 
have an im pressive spec ific ity  o f nearly 1 00%  in pa tients w ith  
rheum atoid arthritis  and have been suggested  to  be involved in 
the d isease pathogenesis. The ta rge ted  ep itopes  are generated 
by a post-translationa l m od ifica tion  cata lysed by the  calcium - 
dependent enzyme peptidyl arg in ine deim inase (PAD), w h ich  
converts positive ly charged a rg in ine to  po lar but uncharged 
citrulline. The aim of th is  s tudy w as to  explore the  e ffec ts  of 
c itru llina tion  on the im m unogenic ity  of au toan tigens as w e ll as 
on po tentia l a rth ritogen ic ity . Thus, im mune responses to  
c itru llina ted  rat serum  album in (C it-R S A) and to  unm od ified  rat 
serum  album in (RSA) w ere  examined as w ell as arth ritis  
deve lopm ent induced by im m unisation w ith  c itru llina ted  rat 
co llagen type  II (C it-C II) or unm od ified  C II. In add ition , to  
corre la te  the presence o f c itru llina ted  p ro te ins  and the  enzyme 
P A D 4 w ith  d iffe ren t s tages of arth ritis , synovial tissues obta ined 
at d iffe rent tim e po in ts  from  rats w ith  co llagen-induced arth ritis  
w ere  examined im m unohistochem ica lly. O u r resu lts 
dem onstrate  tha t c itru llina tion  of the  endogenous antigen R SA 
broke im m unologica l to le rance , as w as evident by the
generation of an tibod ies  d irec ted  aga inst the  m odified  prote in 
and c ross-reacting  w ith  the  native prote in. Furtherm ore w e  
cou ld  dem onstrate  that C it-C II induced arth ritis  w ith  h igher 
inc idence  and earlier onset than d id  the  native counterpart. 
Finally, th is  s tudy reveals that c lin ica l s igns of arthritis  precede 
the p resence  of c itru llina ted  p ro te ins  and the  enzyme PAD4. As 
d isease p rogressed  into a m ore severe and chron ic  sta te , 
p rod u c ts  o f c itru llina tion  appeared spec ifica lly  in the  jo in ts . 
C itru llina ted  p ro te ins  w ere  de tec ted  m ainly in extracellu lar 
depos its  but cou ld  also be found  in in filtrating ce lls  and on the 
cartilage surface. PA D 4 w as de tec ted  in the cytop lasm  of 
in filtrating m ononuclear cells, from  day 21 after im munisation 
and onwards. In conclus ion , our data reveal the  po tency of 
c itru llina tion to  break to le rance  aga inst the  se lf antigen R SA and 
to  increase the  a rth ritogen ic  p roperties  of the cartilage antigen 
CII. W e  a lso show  tha t c itru llina ted  p ro te ins  and the enzyme 
PA D 4 are not de tectab le  in healthy jo in ts , and that the 
appearance and am ounts in a rth ritic  jo in ts  of experim ental 
animals are corre la ted  w ith  the severity of inflammation.
Introduction
The chronic inflammatory jo in t disease rheumatoid arthritis 
(RA) is characterised by synovial inflammation and pannus 
formation, which can lead to severe destruction of cartilage 
and bone. Several self proteins have been suggested as 
disease-driving autoantigens, and the presence of autoan­
tibodies w ith different specificities in patients with RA 
(reviewed in [1,2]) supports the hypothesis of an autoim­
mune aetiology. Rheumatoid factor has for a long time been 
the best-described RA-associated antibody marker, recog­
nising the Fc part of IgG molecules. However, another 
class of autoantibodies has lately gained attention, namely
Anti-CCP =  anti-cyclic citrullinated peptide; anti-MC antibodies =  antibodies against chemically modified citrulline; BSA =  bovine serum albumin; CIA 
=  collagen-induced arthritis; CII =  collagen type II; Cit-CII =  citrullinated CII; Cit-RSA =  citrullinated RSA; DA =  Dark Agouti; ELISA =  enzyme-linked 
immunosorbent assay; FIA =  Freund's incomplete adjuvant; HRP =  horseradish peroxidase; MHC =  major histocompatibility complex; PAD =  peptidyl 
arginine deiminase; PBS =  phosphate-buffered saline; RA =  rheumatoid arthritis; RSA =  rat serum albumin. R458
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antibodies directed against proteins containing the non­
standard amino acid citrulline [3,4].
Citrulline is generated by the deimination of arginine, a 
post-translational modification occurring during apoptosis 
as well as during the terminal differentiation of cells, in both 
healthy and arthritic individuals [5,6]. C itrullination is cata­
lysed by a family of calcium-dependent enzymes named 
peptidyl arginine deiminase (PAD, EC 3.5.3.15) (reviewed 
in [7]). These enzymes are present in several different cell 
and tissue types, including inflammatory cells (PAD2 [8-10] 
and PAD4 [10-12]). PAD4 has been detected in granulo­
cytes infiltrating the synovial tissue in a mouse model of 
arthritis [13] and this enzyme, together with PAD2, has also 
been demonstrated in macrophages from synovial fluid of 
patients w ith RA [10].
The best-described citrulline-reactive autoantibodies asso­
ciated with RA are the following: anti-perinuclear factor 
[14,15] and anti-keratin autoantibodies [16,17], both 
directed against citrullinated filaggrin [18]; anti-Sa autoan­
tibodies [19] directed against citrullinated vimentin [20 ]; 
and antibodies against cyclic citrullinated peptide (anti- 
CCP) [21,22]. These latter autoantibodies have a sensitiv­
ity of up to 8 0 %  and a specificity of 9 8 %  in patients with 
RA [1,22]. Besides this high specificity, these markers are 
present early in disease, even before clinical onset [23,24], 
and they are synthesised locally by plasma cells in the pan­
nus [25,26]. In addition, the existence of citrulline-reactive 
antibodies has been associated w ith a more active and 
severe disease [27-34] and a strong association w ith major 
histocompatibility complex (MHC) shared epitope haplo- 
types [28,35,36] has also been reported.
The accumulated data point towards a link between citrull- 
inated proteins and the pathogenesis of RA. W e therefore 
considered it to be of interest to explore the effects of cit- 
rullination on the immunogenicity of autoantigens and on 
potential arthritogenicity. In the present study we examined 
the responses of rat T and B cells to citrullinated rat serum 
albumin (Cit-RSA) in comparison w ith those of unmodified 
rat serum albumin (RSA). To investigate the clinical arthri- 
togenic relevance of citrullination, the cartilage antigen rat 
collagen type II (CII) was modified and arthritis develop­
ment was evaluated in the experimental rat model collagen- 
induced arthritis (CIA). In addition, to correlate the pres­
ence of citrullinated proteins w ith that of PAD4 w ith differ­
ent stages of arthritis, we examined synovial tissue 
immunohistochemically at different time points of CIA.
Our study demonstrates, for the first time, the kinetics of 
the presence of citrullinated proteins as well as the enzyme 
PAD4 in arthritic jo ints from experimental animals. The 
amounts of citrullinated proteins and the enzyme PAD4 are 
correlated w ith severity of inflammation and are not de tect­
able in healthy joints. The study also reveals that the citru ll­
ination of proteins can break natural tolerance mechanisms 
and increase the arthritogenic properties of CII.
Materials and methods
Animals
Lew.1AV1 and Dark Agouti (DA) rats, originating from the 
Zentralinstitut für Versuchstierzucht, Hannover, Germany, 
were bred, kept and used under pathogen-free conditions 
at the animal department of Karolinska University Hospital, 
Stockholm, Sweden. Animals were fed with standard 
rodent food and water ad libitum. Experiments were per­
formed w ith female Lew.1AV1 or male DA rats, aged 9 to 
14 weeks, with approval from the Stockholm  North Ethical 
Committee.
Preparation and citrullination of antigen
CII was prepared from Swarm 's rat chondrosarcoma by 
pepsin digestion and purification as previously described 
[37,38]. CII was stored freeze-dried at -20°C  until d is­
solved in 0.01 M acetic acid and dialysed against the cit- 
rullination buffer, 0.1 M Tris-HCl (pH 7.6) containing 10 
mM CaCl2 and 5 mM dithiothreitol. RSA (Sigma-Aldrich, 
Steinheim, Germany) was dissolved directly in citrullination 
buffer. Proteins were incubated w ith rabbit skeletal muscle 
PAD (Sigma), at a concentration of 2 U/mg protein, for 2 
hours at 37°C. C itrullination was terminated by adding 20 
mM EDTA and subsequently dialysed successively against 
2 mM EDTA (pH7.6) and M illi-Q water containing 10 mM 
Tris-HCl (pH7.6) at 4°C. Control proteins were treated sim­
ilarly, apart from the addition of PAD. Protein solutions were 
then freeze-dried and stored at -20°C. For experimental 
use, freeze-dried proteins were dissolved in appropriate 
buffer, namely RSA in PBS and CII in 0.01 M acetic acid.
To verify the purity and amount of proteins, aliquots of sam­
ples were run in SDS-PAGE gels followed by Coomassie 
Brilliant Blue staining. Total protein quantification was also 
performed with a modified version of the Bradford method, 
using the Coomassie Plus Protein Assay Reagent Kit 
(Pierce Biotechnology, Rockford, IL, USA) in accordance 
with the manufacturer's instructions. To verify successful 
citrullination, immunoblotting was performed w ith RA3 
[39], a human recombinant antibody directed against c itru l­
line (Fig. 1). In brief, 5 |il of citrullinated CII (Cit-CII), CII, Cit- 
RSA and RSA (concentration 2 mg/ml) were applied to a 
nitrocellulose membrane (BioTrace NT, product no. 
66485; Pall Life Sciences, Ann Arbor, MI, USA). The mem­
brane was incubated for 1 hour in blocking buffer (PBS 
containing 0 .05%  Tween 20 w ith 5%  (w/v) non-fat dried 
milk) then incubated for a further 1 hour w ith primary anti­
body RA3, diluted 1:5 in blocking buffer, at room tem pera­
ture (2 0 -2 5 °C ). After incubation w ith a horseradish 
peroxidase (HRP)-conjugated donkey anti-human antibody 
(diluted 1:1,000 in blocking buffer; Amersham Pharmacia
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Biotech, Little Chalfont, Bucks., UK) for 1 hour at room tem ­
perature, the pro te in-antibody complexes were detected 
by enhanced chemiluminescence w ith the ECL system 
(Amersham Pharmacia Biotech, Uppsala, Sweden).
F igure  1
Cit-CII Cit-RSA
-
CII RSA
Verificationof citrullinationofcollagen type II (CII) and rat serum albu­
min (RSA) by immunoblotting. Using the recombinant anti-citrullinated 
protein antibody RA3, citrulline was detected in the citrullinated CII 
(Cit-CII) sample (upper left) as well as in the citrullinated RSA (Cit- 
RSA) sample (upper right), while uncitrullinated CII (lower left) and 
uncitrullinated RSA (lower right) were negative for citrulline.
Induction and evaluation of clinical disease
To increase the likelihood of detecting citrullinated proteins 
and the enzyme PAD4 in the jo ints of arthritic animals, we 
chose to perform the immunohistochemical stainings in the 
DA rat, because this strain has proven to develop the most 
severe CIA.
In contrast, the Lew.1AV1 rat strain develops a milder d is­
ease and was therefore selected when investigating the 
additive arthritogenic effects of Cit-CII. Lew.1AV1 rats 
were also used when studying the effects of citrullination 
on tolerance to RSA.
F igure  2
Citrullinated proteins are present in the arthritic joint. Positive citrulline 
staining was found in extracellular deposits (a,e), cartilage (c) and infil­
trating cells (d). Unimmunised animals were negative for citrulline (f). 
Immunohistochemical staining was performed with RA3, a human 
recombinant anti-citrullinated protein antibody. Control staining was 
performed with an isotyped-matched recombinant human anti-U1-70K 
antibody (b). (Original magnifications: x100  (a,b); x250  (c); x400  (d); 
x40  (e,f)).
ance w ith a previously described procedure [40]. Each 
paw was divided into three groups of joints, the interphalan- 
geal jo ints of the digits, the metacarpophalangeal and wrist 
jo ints in the forepaws and the metatarsophalangeal and 
ankle jo ints in the hind paws. In brief, 1 point signifies swell­
ing of one group of joints, 2 points signifies two groups of 
swollen joints, 3 points signifies three groups of swollen 
joints and 4 points signifies swelling of the entire paw. The 
maximum score was thus 16 for each rat.
Anaesthetised rats were immunised in the base of the tail: 
male DA rats with 150 |ig  of CII dissolved in 100 |il of 0.01 
M acetic acid, emulsified w ith an equal volume of Freund's 
incomplete adjuvant (FIA; Difco, Detroit, MI, USA) (intrader- 
mally); female Lew.1AV1 rats w ith 120 |ig  of CII or Cit-CII 
dissolved in 100 |il of 0.01 M acetic acid plus 100 |il of FIA 
(intradermally) or w ith 180 |ig of RSA or C it-RSA dissolved 
in 150 |il of PBS plus 150 |il FIA (subcutaneously). The ani­
mals immunised with CII and Cit-CII were monitored for 
signs of arthritis from day 12 after immunisation, in accord-
Evaluation of serum anti-RSA and anti-Cit-RSA antibody 
levels
Individual serum samples from Lew.1AV1 rats immunised 
with RSA and C it-RSA were obtained at different time 
points, namely 12, 24 and 35 days after immunisation (by 
tail bleeding) as well as at 61 days after immunisation (by 
heart puncture). ELISA plates (96-well Maxisorp; Nunc, 
Roskilde, Denmark) were coated w ith 10 |ig /m l RSA or Cit- 
RSA (diluted in PBS), overnight at 4°C. Plates were 
washed w ith PBS-Tween (0.05%) and sera (serially diluted
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in PBS containing 0 .05%  Tween) were added in duplicate. 
After 2 hours of incubation at room temperature, plates 
were washed as above and incubated w ith alkaline phos­
phatase-conjugated goat anti-rat IgG (diluted 1:5,000 in 
PBS containing 0 .05%  Tween; Jackson Immunoresearch 
Lab, W est Grove, PA, USA) for a further 2 hours at room 
temperature. Finally, a phosphatase substrate (Sigma, St 
Louis, MO, USA) was added and absorbance was deter­
mined at 405  nm with an Emax precision microplate reader 
(Molecular Devices).
To investigate the risk of contamination by PAD in our Cit- 
RSA sample, giving a false positive result in our C it-RSA 
ELISA, we performed an anti-PAD ELISA. Plates were 
coated w ith the same amount of PAD expected to contam ­
inate the C it-RSA sample in the C it-RSA ELISA, namely 
0 .0432 |ig /m l. The ELISA was performed w ith the same 
procedure as described for C it-RSA and RSA (see above).
In addition, to quantify antibodies specific for anti-citrulli- 
nated protein, an in-house C C P ELISA was used. Control 
reactions w ith corresponding cyclic arginine-containing 
peptides were also included. In brief, Streptawell plates 
were coated with 1 |ig  of biotinylated cfc1-cyc citrullinated 
peptide or cf0-cyc control peptide (diluted in PBS, 0.1%  
BSA) overnight at 4°C. Rat serum samples (diluted 1:50 in 
PBS containing 0 .05%  Tween and 1% BSA) were added 
in duplicate and incubated for 1 hour in a 37°C  humid 
chamber. Plates were washed before the addition of HRP- 
conjugated rabbit anti-rat IgG (Sigma P216; diluted 
1:1,000 in PBS containing 0 .05%  Tween and 1% BSA), 
followed by incubation for 1 hour in a humid chamber at 
37°C. Bound antibodies were revealed by the addition of 
3,3',5,5'-tetramethylbenzidine (Sigma). The enzymic reac­
tion was stopped w ith 0.5 M H 2S O 4 after 30 min, and 
absorbance was determined at 450 nm.
In vitro T cell proliferation in response to stimulation 
with RSA and Cit-RSA
Inguinal lymph nodes from Lew.1AV1 rats immunised with 
RSA and C it-RSA were removed 10 days after immunisa­
tion; single-cell suspensions were prepared and resus­
pended in Dulbecco's modified Eagle's medium 
supplemented w ith glutamine, penicillin, streptomycin, 
HEPES and 10%  fetal calf serum (Life Technologies, 
Paisley, Renfrewshire, UK). Cells were cultured in vitro for 
72 hours at 106 cells per well in triplicate (96-well fla t-bot­
tomed culture plates; Nunc) in the presence of RSA (10 
|ig/m l), C it-RSA (10 |ig/m l), PBS or concanavalin A (2 |ig / 
ml; Sigma-Aldrich). [3H]Thymidine (PerkinElmer Life S c i­
ences Inc., Boston, MA, USA), was added (1 |iC i per well) 
for the final 16 hours of culture. Cells were harvested with 
a Tomtec cell harvester and [3H]thymidine incorporation 
was measured as counts per minute (c.p.m.) in a W allac 
Trillux 1450 microbeta counter. Stimulation was calculated
and expressed as stimulation index (C.p.m. after stimula- 
tion/C.p.m. of background).
Antibodies
Recombinant anti-citrullinated protein single-chain variable 
fragment (scFv) antibody RA3, selected from RA-patient- 
derived phage display libraries and control scFv human 
anti-U1-70K have been described elsewhere [39]. Rabbit 
antibodies directed against chemically modified citrulline 
(anti-MC antibodies), developed by Dr Tatsuo Senshu and 
colleagues [5,41], were purchased from Upstate B iochem ­
icals (Lake Placid, NY, USA). Polyclonal antibodies recog­
nising PAD4 (SN823) were produced by immunising 
rabbits with PAD4 isotype-specific peptides (amino acids 
210 to 225 and 51 7 to 531) and by affinity purification with 
a CNBr-activated Sepharose 4B  column, as described pre­
viously [10]. Preimmune rabbit IgG was used as control for 
PAD4.
Immunohistochemical analysis
Zamboni-fixed [42] cryopreserved sections of synovial tis ­
sue from CII-immunised DA rats were stained for expres­
sion of citrullinated proteins and PAD4. Endogenous 
peroxidase activity was blocked by treatment for 30 min in 
darkness at room temperature w ith 1% hydrogen peroxide 
and 2%  sodium nitride dissolved in PBS. After washing 
with PBS, 2%  normal goat serum was added to block non­
specific binding sites. Sections were then incubated with 
200 |il of primary antibody (RA3 (undiluted) or anti-PAD4 
(diluted 1:24)) overnight in a humid chamber at 4°C. An 
isotype-matched recombinant human anti-U1-70K anti­
body and a preimmune rabbit IgG were used as respective 
controls. S lides were then washed in PBS before incuba­
tion w ith 200 |il of appropriate biotin-labelled secondary 
antibody (donkey anti-human IgG (Jackson Immuno 
Research) diluted 1:1,000 or goat anti-rabbit IgG (Vector, 
Burlingame, CA, USA) diluted 1:800) for 1 hour at room 
temperature. After further washing, 200 |il of avidin-biotin- 
HRP (Vectastain; Vector) prepared in accordance w ith the 
manufacturer's directions was applied for 60 min at room 
temperature. A final wash was followed by addition of the 
substrate diaminobenzidine (Peroxidase Substrate Kit; 
Vector) for 5 min. The colour reaction was stopped by 
washes in tap water, after which sections were counter­
stained with Mayer's haematoxylin. Finally the slides were 
dried and mounted w ith buffered glycerol, and evaluation 
was performed by m icroscopy with a Polyvar II m icroscope 
(Reichert-Jung, Vienna, Austria) connected to a charge­
coupled device colour camera (DXC-750P; Sony Corp., 
Tokyo, Japan).
In addition, anti-M C antibodies were used to confirm  the 
citrulline staining obtained w ith RA3. Before incubation 
with primary antibody, sections were treated for 3 hours at 
37°C  in a chemical modification solution consisting of one
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Table  1
C o rre la tion  o f presence o f c itru llin a te d  p ro te ins  and pep tidy l a rg in in e  de im inase  4 w ith  degree  o f in fla m m a tio n
Days a fte r im m unisation A rth ritis  score  Ce ll in filtration C artilage
destruction
C itru lline-positive
deposits
C itru lline-positive
cells
C itru lline-positive
cartilage
P A D 4-positive
cells
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
3 0.0 0.0 0.0 0.0 0.0 0.0 0.0
6 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15 3.3  ±  2.4 1.3 ±  0.5 0.0 0.0 0.0 0.0 0.0
21 9.8 ±  3.3 1.8 ±  0.5 0.5 ±  0.6 1.0 0.5 ±  0.6 0.8 ±  1.0 1.0 ±  0.5
28 11.0 ±  3.5 3.0 2.5 ±  0.6 1.8 ±  1.0 1.3 ±  0.5 1.5 ±  1.3 1.5 ±  0.4
38 11.8 ±  2.6 3.0 3.0 2.7 ±  0.6 1.8 ±  0.5 0.5 ±  0.6 2.2 ±  0.5
PAD4, peptidyl arginine deiminase 4. Arthritic score, cell infiltration, cartilage destruction and presence of citrullinated proteins in extracellular 
deposits, cells and cartilage were evaluated at different time points of collagen-induced arthritis. All data are from four rats, evaluated in a blinded 
manner by two independent evaluators and are means ±  SD. Arthritis score ranges from 0 to 16 as explained in the Materials and methods section. 
Arbitrary units were used for the other features, ranging from 0, indicating no cell infiltration, cartilage destruction, presence of citrullinated proteins 
or PAD4, to 3, indicating extensive cell infiltration, cartilage destruction, presence of citrullinated proteins and PAD4.
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Peptidyl arginine deiminase 4 (PAD4) is present in the arthritic joint. 
PAD4 was detected in infiltrating cells (a), localised to the cytoplasm of 
mononuclear cells (c,e). Unimmunised animals were negative for PAD4 
staining (f). Immunohistochemical stainings were performed with a rab­
bit anti-PAD4 antibody. Control staining was performed with preim- 
mune rabbit sera (b,d) (Original magnifications: x40  (a,b,f); x200  (c­
e)).
part solution A (0.025%  (w/v) FeCl3, 4.6 M H2S O 4, 3.0 M 
H3PO4) plus one part solution B (0.5%  diacetyl monoxime, 
0 .25%  antipyrine, 0.5 M acetic acid) (anti-Citrulline (M odi­
fied) Detection Kit; Upstate Biochemicals). Control sec­
tions were incubated in a solution containing one part 
solution A and one part M illi-Q  water. After extensive wash­
ing in PBS, slides were incubated for 40 min at room tem ­
perature w ith 1% H2O 2, washed in PBS and incubated for 
30 min at room temperature w ith 5%  normal goat serum in 
PBS plus 1% BSA. Primary antibody (anti-MC), diluted 
1:1,000 in PBS plus 1% BSA, was added and slides were 
incubated overnight at room temperature. S lides were then 
washed in PBS, followed by incubation for 30 min at room 
temperature w ith secondary antibody (biotinylated goat 
anti-rabbit IgG; Vector) diluted 1:800 in PBS plus 1% 
BSA. The subsequent steps were performed as described 
above.
Statistical analysis
All data were evaluated w ith the M ann-W hitney U-test for 
independent groups, except for arthritis incidence, which 
was evaluated by Kaplan-M eier survival analysis.
Results
Presence of citrullinated proteins and PAD4 in the 
arthritic joints correlates with the degree of 
inflammation
To examine the presence of citrullinated proteins and the 
enzyme PAD4 in the jo ints at different stages of experimen­
tal arthritis, histological analyses of rat ankle jo ints were 
performed by immunohistochemistry. Citrullinated proteins 
could be detected in the joints of arthritic animals with the 
RA3 antibody (Fig. 2 and Table 1). The first appearance of 
protein citrullination was noted after disease onset, at day 
21 after immunisation, and increased staining was 
observed as the disease progressed into a more severe,
R462
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F igure  4
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Immunisation with citrullinated rat serum albumin (Cit-RSA) breaks immunological tolerance on the B cell side. Immunisation with Cit-RSA (white 
bars) induced an antibody response against Cit-RSA (a), cross-reacting with unmodified rat serum albumin (RSA) (b) at all time points investigated, 
whereas immunisation with RSA (black bars) did not. Sera were collected 12, 24, 35 and 61 days after immunisation, and total IgG was measured 
by ELISA as OD at 405 nm. Results are means ±  SD (n =  7 animals per group), representative of two replicate experiments. **P <  0.01 at all time 
points.
12 61
chronic state (namely 28 and 38 days after immunisation). 
Unimmunised animals and time points before clinical signs 
of arthritis (namely 0, 3, 6 and 10 days after immunisation) 
as well as the time of disease onset (namely 15 days after 
immunisation) were negative for citrulline. Some infiltrating 
cells as well as the cartilage surface stained positively for 
citrulline and the major sources of citrullinated proteins in 
the arthritic jo int were extracellular deposits, presumably 
fibrin deposits. The occurrence of citrullinated proteins in 
the jo ints is specific, because other investigated organs 
such as lung, ear, spinal cord, spleen, lymph nodes and sal­
ivary glands were all negative (data not shown).
For comparison w ith previous studies in humans [43] and 
mice [13] we also used antibodies targeting chemically 
modified citrulline. This method circumvents the risk of 
epitope blocking by residues flanking citrulline, because 
the citrulline side-chain becomes so bulky through the 
chemical modification that antibody recognition cannot be 
influenced by other amino acids [5,41]. Here we confirmed 
the results obtained w ith RA3. A similar staining pattern 
was observed, w ith positive cells, cartilage and extracellular 
deposits, whereas control stainings of non-modified sec­
tions were negative (data not shown).
PAD4, which has been reported to be present in mouse 
and human arthritic synovia [10,13], could also be 
detected in synovial tissue of this rat arthritis model from 21 
days after immunisation (Fig. 3 and Table 1). The number of 
positive cells localised to the synovial infiltrate increased by 
days 28 and 38 after immunisation. PAD4 was not evident 
in healthy synovial tissue, nor in sections from 3, 6 and 10 
days after immunisation; although an apparent inflammation 
was observed, PAD4 could not be detected 15 days after 
immunisation.
F igure  5
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In vitro proliferativeresponses to rat serum albumin (RSA) and to citrull­
inated RSA (Cit-RSA). Stronger T cell responses to Cit-RSA (statisti­
cally significant) and to RSA (a trend) were observed in animals 
immunised with Cit-RSA (white bars) than in animals immunised with 
unmodified RSA (black bars). As previously shown (Fig. 4), the animals 
immunised with Cit-RSA developed a B cell response to RSA and to 
Cit-RSA, whereas the animals immunised with RSA did not. The dotted 
line suggests a hypothetical threshold that it is necessary to reach to 
induce B cell help and subsequent antibody production. Single cell 
suspensions were prepared from inguinal lymph nodes 10 days after 
immunisation, and stimulation index (S.I.) was calculated after 72 hours 
of culture in the presence of RSA or Cit-RSA (10 ^g/ml). Results are 
means ±  SD (n =  7 animals per group), representative of two replicate 
experiments. *P <  0.05.
Citrullination of a non-immunogenic antigen breaks B 
cell tolerance
Lew.1AV1 rats were immunised w ith the non-immunogenic 
autoantigen RSA or the modified counterpart C it-RSA and 
the differences in induced immune responses were ana­
lysed in vitro. The kinetics of the antigen-specific IgG
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F igure  6
(a) (b)
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Citrullination of collagen type II (CII) increases its arthritogenic properties. Lew.1AV1 rats developed disease with higher incidence (a) and earlier 
onset as well as a trend towards higher mean arthritic score among the affected animals (b) when immunised with citrullinated CII (Cit-CII) (open 
squares) than when immunised with unmodified CII (filled circles). Rats were immunised with Cit-CII or unmodified CII and monitored for signs of 
arthritis for the next 30 days. Incidence (a) and mean score of sick animals (b) were calculated. Data include 20 animals per group from two pooled 
experiments. *P <  0.05.
*
response was investigated and the results revealed not 
only a response towards the modified protein, but also 
cross-reactivity to the unmodified form of RSA (Fig. 4). Anti­
bodies were detected from 12 days after immunisation, had 
increased by day 24 after immunisation and persisted for a 
further 40 days. Cross-reactivity was demonstrated at all 
time points. No B cell response was noted in animals immu­
nised w ith unmodified RSA.
Animals immunised with C it-RSA and RSA were also 
tested for anti-PAD IgG responses. The anti-PAD ELISA 
was negative both for animals immunised w ith C it-RSA and 
for animals immunised w ith RSA (data not shown), 
indicating that the amount of PAD contaminating the Cit- 
RSA sample did not result in any false positive result in the 
C it-RSA ELISA, described above.
Immunisation with Cit-CII increases arthritis incidence 
and accelerates clinical onset of disease
Unmodified or citrullinated rat CII was, together with adju­
vant, injected into Lew.1AV1 rats; arthritis development 
was monitored by blinded m acroscopic evaluation. The c it­
rullinated form of CII induced arthritis w ith significantly 
higher incidence and earlier onset than did the same 
amount of unmodified CII (Fig. 6). The incidence was 35%  
higher in the C it-RSA group during the early phase of the 
disease and 15%  higher during the end stage. Disease 
onset in this group occurred 13 days after immunisation, 
compared w ith 16 days after immunisation in the control 
group. A trend towards higher mean arthritis score was 
also observed in the affected animals in the Cit-CII group 
compared w ith the CII group, although this was not statis­
tically significant.
In addition, by performing both an anti-CCP ELISA and a 
control ELISA containing cyclic arginine-containing pep­
tides, we could confirm that the animals immunised with 
C it-RSA produced antibodies against citrullinated epitopes 
and also antibodies recognising arginine epitopes (data not 
shown).
The T cell response was evaluated by [3H]thymidine incor­
poration 10 days after immunisation, as depicted in Fig. 5. 
Here, a proliferative response was demonstrated in animals 
immunised w ith unmodified RSA, both when stimulated 
with the same antigen and when stimulated w ith the citru ll­
inated antigen. Cells from animals immunised w ith C it-RSA 
showed a stronger proliferation than the RSA-immunised 
rats in response to the modified protein. The same ten­
dency was observed when using RSA as a stimulus, 
although it was not statistically significant.
Discussion
The production of anti-citrullinated protein antibodies is 
almost 100%  specific for patients w ith RA, indicating an 
important role for citrullinated proteins in the pathogenesis 
of RA. W e therefore considered it of interest to investigate 
the ability to break immunological tolerance by the citru lli­
nation of endogenous proteins. Our data reveal that citrull- 
ination of the non-immunogenic antigen RSA induced an 
antibody response against the citrullinated protein with 
cross-reactivity to the unmodified protein at all time points 
investigated. The observation that anti-RSA IgG titres 
declined by 61 days after immunisation, as opposed to anti- 
cit-RSA IgG titres, might be due to affinity maturation of the 
B cell response w ith bias towards the citrullinated 
'neoepitope'. Another possibility could be the formation of 
RSA antibodies and RSA immune complexes, which would 
increase their clearance from the circulation.
W e could record an ex vivo proliferative T cell response to 
RSA as well as to C it-RSA in rats immunised w ith modified 
protein and also in rats immunised with the unmodified pro-
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tein, as demonstrated by stimulation index values over 1.0. 
W hen comparing the proliferative responses to C it-RSA, 
cells from animals immunised w ith the citrullinated protein 
demonstrated a significantly stronger response than cells 
from animals immunised w ith the unmodified protein (P  <  
0.05). A similar trend was detected when comparing the 
responses of T cells to RSA, but the difference did not 
reach statistical significance. This indicates that RSA, 
together with a strong adjuvant, can induce an autoreactive 
T cell response, although this is not sufficient to induce B 
cell help. In contrast, immunisation w ith C it-RSA induced a 
stronger T cell response that could confer B cell help, as 
depicted in Fig. 4.
Furthermore, Cit-CII induced arthritis w ith earlier onset and 
higher incidence than unmodified CII after immunisation. 
Considering the low arginine content of CII, our results indi­
cate that protein modification by the conversion of arginine 
to citrulline is a highly potent mechanism for increased 
autoreactivity. Previous studies have demonstrated that 
anti-CII antibody titres do not reflect disease severity in this 
model of C IA and that stimulation in vitro w ith homologous 
CII does not induce T cell proliferation. W e therefore chose 
not to analyse the humoral or cellular responses to CII in 
these animals.
Several post-translational protein modifications, especially 
those related to apoptosis [44,45], are associated with 
autoimmunity [46-49]. Inefficient clearance of these modi­
fied proteins in an inflammatory environment, conveying 
'danger signals' to the immune system, might in combina­
tion w ith the appropriate M H C  haplotype override to ler­
ance mechanisms and activate autoreactive T cells. 
Citrullination interferes w ith organised protein structure, 
contributes to protein unfolding and to increased suscepti­
bility to digesting enzymes [50,51], which could lead to 
altered antigen uptake, processing and presentation. 
Indeed, citrullinated peptides have been reported to bind 
more efficiently to the RA-associated HLA-DRB1*0401 
haplotype than do non-citrullinated peptides [52]. As to ler­
ance has not been established to such peripherally modi­
fied self-peptides, citrullination might increase the risk of 
activating pathogenic T cells. Our data therefore demon­
strate not only the potency of citrullinated proteins to break 
tolerance, as evident from our experiments w ith RSA, but 
also the increased arthritogenic properties of Cit-CII.
Because anti-citrullinated protein antibodies can be 
detected in RA sera before clinical signs of disease [24], 
we speculate that citrullination of synovial proteins might 
occur at time points before RA becomes manifest. It is not 
ethically possible to examine the synovial tissue of healthy 
individuals at risk of developing RA. However, this 
becomes feasible with the use of an experimental model. In 
the present study we examined, for the first time, the kinet­
ics of the presence of citrullinated proteins and the citrulli- 
nating enzyme PAD4 in jo ints during arthritis development. 
In this experimental model of homologous CIA w ith 100%  
disease incidence, citrullinated proteins and PAD4 were 
not detectable before clinical signs of arthritis. Rather, as 
inflammation proceeded, increasing amounts of citrulli- 
nated proteins and PAD4 were detected specifically in the 
joints. Extracellular deposits constitute the major source of 
citrullinated proteins in the inflamed joint, although both 
cells and cartilage also contribute to the positive staining. 
Although PAD4 has been described to have a nuclear 
localisation [12], our stainings clearly demonstrate the 
presence of this enzyme in the cytoplasm of infiltrating 
mononuclear cells. Our inability to detect nuclear staining 
of PAD4 might be due to the absence of permeabilising 
agents during staining procedures. Our finding that citrulli- 
nated synovial proteins could not be encountered before 
disease onset might explain the failure in detecting anti-cit- 
rullinated protein antibodies in animal models. Perhaps the 
presence of citrullinated proteins in these arthritis models 
is not disease-initiating, but rather a result of inflammation. 
This is also supported by the observation that citrullinated 
proteins can be detected in inflamed synovial tissue of non- 
RA patients lacking the anti-citrulline-specific B cell 
response [53,54].
Taking together our findings and those of others, we 
hypothesise that in individuals with the appropriate genetic 
background a subclinical inflammation that induces citrulli­
nation of endogenous proteins w ill generate a pathogenic 
immune response against the modified proteins and that 
through the production of autoantibodies a chronic inflam­
mation will be established. An immune response towards 
any citrullinated protein is clearly not enough to induce 
clinical arthritis, as demonstrated by the lack of signs of d is­
ease in the Cit-RSA-immunised animals. Both genetic and 
environmental factors most probably contribute to the 
development of arthritis. The initiation of citrulline reactivity 
does not necessarily need to occur in the joints. For exam­
ple, smoking has been reported to be an environmental risk 
factor for RA in individuals w ith M H C  shared epitope [55]. 
It is plausible that smoking could induce such an inflamma­
tory reaction in lungs with the formation of citrullinated pro­
teins. W hy an autoreactivity to citrullinated proteins would 
precipitate in arthritis and not in other organ-specific inflam­
matory diseases is currently unknown. However, several 
reports indicate that jo ints are especially sensitive to inflam­
matory stimuli. The experimental model oil-induced arthritis 
demonstrates that administration of the non-antigenic adju­
vant mineral oil at a distant location (namely the tail base) 
induces arthritis and no other disease in rats [56]. A ddition­
ally, systemic overexpression of proinflammatory cytokine 
TNF generates a jo int-specific inflammation [57]. Similarly, 
interleukin-1Ra knockout mice develop arthritis [58].
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Conclusion
Our data reveal the potency of citrullination to break to ler­
ance against the ubiquitous systemic self antigen RSA and 
to increase the arthritogenicity of the tissue-specific protein 
CII. Furthermore, we have demonstrated that the amounts 
of citrullinated proteins and the enzyme PAD4 in the 
arthritic jo ints of experimental animals correlated w ith the 
severity of inflammation, while no citrullinated proteins or 
PAD4 could be detected in healthy joints. On the basis of 
our new data and previous findings on this top ic  we hypoth­
esise that a subclinical inflammation might induce citrullina­
tion of endogenous proteins. This citrullination does not 
necessarily need to occur in joints but can occur elsewhere 
in the body. In combination with a certain genetic context, 
anti-citrullinated protein antibodies will be generated, 
which will potentiate an inflammatory trigger in jo ints and 
thereby initiate RA.
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